These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2861983)

  • 1. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates.
    Walle T
    Drug Metab Dispos; 1985; 13(3):279-82. PubMed ID: 2861983
    [No Abstract]   [Full Text] [Related]  

  • 2. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
    Walle T; Wilson MJ; Walle UK; Bai SA
    Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective ring oxidation of propranolol in man.
    Walle T; Walle UK; Wilson MJ; Fagan TC; Gaffney TE
    Br J Clin Pharmacol; 1984 Nov; 18(5):741-8. PubMed ID: 6508983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    Lankford SM; Maskasame C; Bai SA
    Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity.
    von Bahr C; Hermansson J; Lind M
    J Pharmacol Exp Ther; 1982 Aug; 222(2):458-62. PubMed ID: 7097564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma.
    Silber B; Riegelman S
    J Pharmacol Exp Ther; 1980 Dec; 215(3):643-8. PubMed ID: 7441523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective oxidative metabolism of propranolol in the microsomal fraction from rat and human liver. Use of deuterium labeling and pseudoracemic mixtures.
    Nelson WL; Shetty HU
    Drug Metab Dispos; 1986; 14(4):506-8. PubMed ID: 2874001
    [No Abstract]   [Full Text] [Related]  

  • 11. N-dealkylation of propranolol in rat, dog, and man. Chemical and stereochemical aspects.
    Nelson WL; Bartels MJ
    Drug Metab Dispos; 1984; 12(3):345-52. PubMed ID: 6145562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stereoselective glucuronidation of beta-blocking agents, 1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32) and propranolol, in animals, in vivo and in vitro].
    Honma S; Ito T; Matsuki Y
    Yakugaku Zasshi; 1986 May; 106(5):406-13. PubMed ID: 2876088
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration.
    Imai T; Yoshigae Y; Hosokawa M; Chiba K; Otagiri M
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1234-42. PubMed ID: 14534358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 17. Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites.
    Walle T; Gaffney TE
    J Pharmacol Exp Ther; 1972 Jul; 182(1):83-92. PubMed ID: 5041658
    [No Abstract]   [Full Text] [Related]  

  • 18. Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration.
    Ritschel WA; Shaaya AN; Tan HS
    Methods Find Exp Clin Pharmacol; 1985 Jun; 7(6):307-13. PubMed ID: 3932795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of benidipine hydrochloride in rats and dogs.
    Kobayashi H; Kobayashi S; Inoue A; Oka T; Nakamizo N
    Arzneimittelforschung; 1988 Nov; 38(11A):1750-3. PubMed ID: 3219154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.